NEW YORK (GenomeWeb) – Roka Bioscience said in its Form 10-Q this week that it exercised an option to reduce the royalty rate it pays to Hologic. As a result, Roka paid $8 million and issued 865,063 shares of its common stock to Hologic subsequent to the closing of Roka's initial public offering last month. The option was exercisable if Roka raised less than $55 million in net proceeds from the IPO. Net proceeds from the offering were about $53.4 million, Roka said in its SEC document.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.